APA Citation
Carhart-Harris, R., Erritzoe, D., Williams, T., & others, . (2012). Neural correlates of the psychedelic state as determined by fMRI studies with psilocybin. *Proceedings of the National Academy of Sciences*, 109(6), 2138-2143.
Summary
This neuroimaging study examined brain activity during psilocybin experiences, finding that the psychedelic state involves decreased activity in key brain regions, particularly the default mode network (associated with self-referential thought and ego). This suggests psychedelics work not by activating the brain but by reducing constraints on consciousness, temporarily dissolving the rigid patterns of normal selfhood.
Why This Matters for Survivors
Emerging research suggests psychedelic-assisted therapy may help with treatment-resistant depression and trauma—conditions common among survivors of narcissistic abuse. Understanding how psychedelics affect the brain's self-referential processes helps explain their potential for shifting rigid patterns of thinking and self-perception that trauma can create.
What This Research Establishes
Psychedelics reduce brain activity in key regions. Contrary to assumptions about “expanded consciousness,” psilocybin decreases activity in the default mode network and other regions, suggesting psychedelics work by reducing constraints.
The default mode network relates to ego. This network, associated with self-referential thought and sense of self, shows reduced activity during psychedelic experiences, correlating with experiences of ego dissolution.
Temporary loosening of rigid patterns. By reducing activity in self-referential brain regions, psychedelics may temporarily loosen the rigid patterns that characterize normal—and traumatized—consciousness.
Implications for therapy. Understanding how psychedelics affect self-referential processing has implications for their therapeutic use in depression, PTSD, and other conditions.
Why This Matters for Survivors
Potential future treatment. Clinical trials suggest psychedelic-assisted therapy may help with treatment-resistant depression and PTSD—conditions common among narcissistic abuse survivors. Understanding mechanisms informs expectations.
Loosening rigid self-perception. Survivors often develop rigid self-perceptions from abuse—worthlessness, self-blame. If psychedelics loosen rigid patterns, they may eventually support recovery by allowing new self-understanding.
This is emerging science. While promising, psychedelic therapy requires appropriate clinical settings and professional guidance. This research explores mechanisms; it’s not a recommendation for self-treatment.
Future possibilities. As research advances, psychedelic-assisted therapy may become available as a treatment option for some survivors dealing with treatment-resistant conditions.
Clinical Implications
Stay informed about emerging treatments. Psychedelic-assisted therapy is advancing rapidly. Clinicians should be aware of research developments and appropriate referral options as they become available.
Understand mechanisms. For patients interested in psychedelic therapy, explain the neuroscience—how these substances affect self-referential processing—to set appropriate expectations.
Ensure appropriate settings. If psychedelic therapy becomes available, ensure patients access it through appropriate clinical protocols with qualified providers, not self-administration.
Connect to trauma mechanisms. Understanding how psychedelics affect rigid self-referential patterns helps explain potential benefits for trauma survivors.
How This Research Is Used in the Book
Carhart-Harris’s research is referenced in chapters on emerging treatments:
“Robin Carhart-Harris’s neuroimaging research reveals something surprising: psychedelics decrease activity in brain regions associated with selfhood, temporarily loosening the rigid patterns of normal consciousness. For trauma survivors, whose self-perception may have become rigidly negative—‘I’m worthless, I deserved it, I can never heal’—this temporary loosening may eventually support new understanding. Clinical trials on psychedelic-assisted therapy for PTSD and depression show promise. This is emerging science requiring professional guidance, but it represents a potential frontier in healing from the neurobiological effects of abuse.”
Historical Context
This 2012 study was part of the resurgence of psychedelic research after decades of prohibition. Carhart-Harris’s work at Imperial College London helped establish the neuroscience underlying psychedelic experiences, paving the way for clinical trials.
Further Reading
- Griffiths, R.R., et al. (2016). Psilocybin produces substantial and sustained decreases in depression and anxiety. Journal of Psychopharmacology, 30(12), 1181-1197.
- Mithoefer, M.C., et al. (2019). MDMA-assisted psychotherapy for PTSD. The Lancet Psychiatry, 6(7), 580-590.
- Carhart-Harris, R.L., & Friston, K.J. (2019). REBUS and the anarchic brain. Pharmacological Reviews, 71(3), 316-344.
About the Author
Robin Carhart-Harris, PhD is Professor at University of California San Francisco and former head of the Centre for Psychedelic Research at Imperial College London. He is one of the leading researchers in the renaissance of psychedelic science.
Historical Context
Published in 2012, this study was part of the early resurgence of psychedelic research after decades of prohibition. Carhart-Harris's work helped establish the neuroscience of psychedelics, paving the way for clinical trials on depression, PTSD, and addiction.
Frequently Asked Questions
Contrary to assumptions, psilocybin decreases activity in key brain regions, particularly the default mode network. Rather than activating the brain, psychedelics appear to reduce constraints, temporarily dissolving normal patterns of selfhood.
A brain network active during self-referential thought—thinking about yourself, your past, your worries. It's associated with the sense of ego or self. Reduced activity in this network during psychedelics correlates with experiences of ego dissolution.
Trauma often creates rigid patterns of self-perception and thought. Psychedelics may temporarily loosen these patterns, potentially allowing new perspectives. Clinical trials are exploring psychedelic-assisted therapy for PTSD and depression.
As of this research (2012), psychedelics remain controlled substances in most jurisdictions. However, clinical trials are ongoing, and some jurisdictions have begun allowing medical use. Consult current regulations and qualified providers.
Survivors often develop rigid self-perceptions—worthlessness, self-blame—from abuse. If psychedelics help loosen rigid patterns, they may eventually support recovery by allowing new self-understanding. This is speculative and requires professional guidance.
Carhart-Harris's work suggests psychedelics temporarily dissolve normal ego boundaries by reducing default mode network activity. This 'ego dissolution' may allow perspective on usually automatic patterns of self-perception.
Psychedelics carry risks and should only be used in appropriate clinical settings with professional guidance. This research explores mechanisms; it's not a recommendation for self-treatment. Clinical trials show promise with careful protocols.
Psychedelic research is rapidly advancing, with clinical trials for PTSD, depression, addiction, and other conditions. Results have been promising, though more research is needed. This may eventually become a treatment option for some survivors.